Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$128.91 USD
+0.68 (0.53%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $128.84 -0.07 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Neurocrine Biosciences, Inc. has a market cap of $12.72B, which represents its share price of $128.23 multiplied by its outstanding shares number of 99.18M. As a large-cap company, NBIX's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
NBIX 128.91 +0.68(0.53%)
Will NBIX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for NBIX
Neurocrine (NBIX) Receives Upgraded Price Target After Strong Earnings
Guggenheim Raises Price Target for NBIX, Maintains "Buy" Rating | NBIX Stock News
Neurocrine price target raised by $10 at Guggenheim, here's why
NBIX: RBC Capital Maintains Rating but Lowers Price Target | NBIX Stock News
NBIX: Stifel Raises Price Target to $174, Reiterates Buy Rating | NBIX Stock News